Novartis traded at 134.06 this Friday November 13th, decreasing 0.16 or 0.12 percent since the previous trading session. Looking back, over the last four weeks, Novartis lost 9.29 percent. Over the last 12 months, its price rose by 28.39 percent. Looking ahead, we forecast Novartis to be priced at 131.30 by the end of this quarter and at 123.35 in one year, according to Trading Economics global macro models projections and analysts expectations.
Novartis AG is a Switzerland-based pharmaceutical company. The Company develops, manufactures, and markets branded and generic prescription drugs, active pharmaceutical ingredients (APIs), biosimilars and ophthalmic products. The Company uses science and digital technologies for treatments in the disease areas of immunology, dermatology, cancer, ophthalmology, neuroscience, respiratory, cardiovascular, renal and metabolism. The business activities of the Company are divided into two segments: Innovative Medicines, which includes innovative patent-protected prescription medicines for blood pressure, cancer and other ailments, and Sandoz, which includes generic pharmaceuticals and biosimilars.